Cargando…
Ruxolitinib does not completely abrogate the functional capabilities of TLR4/9 ligand-activated NK cells
INTRODUCTION: Natural killer (NK) cells are lymphocytes from the innate immune system part of the first defense barrier against infected and transformed cells, representing 5%-15% of peripheral blood lymphocytes. The cytotoxic capacity of NK cells is controlled by a balance between inhibitory and ac...
Autores principales: | Mestre-Durán, Carmen, Martín-Cortázar, Carla, García-Solís, Blanca, Pernas, Alicia, Pertíñez, Lidia, Galán, Víctor, Sisinni, Luisa, Clares-Villa, Laura, Navarro-Zapata, Alfonso, Al-Akioui, Karima, Escudero, Adela, Ferreras, Cristina, Pérez-Martínez, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851469/ https://www.ncbi.nlm.nih.gov/pubmed/36685552 http://dx.doi.org/10.3389/fimmu.2022.1045316 |
Ejemplares similares
-
P1428: IMPLICATIONS OF THE RUXOLITINIB (JAK1/JAK2 INHIBITOR) ON GRAFT-VERSUS-LEUKAEMIA EFFECT MEDIATED BY THE NK CELL.
por: Durán, C., et al.
Publicado: (2022) -
Donor selection for adoptive cell therapy with CD45RA(−) memory T cells for patients with coronavirus disease 2019, and dexamethasone and interleukin-15 effects on the phenotype, proliferation and interferon gamma release
por: Al-Akioui-Sanz, Karima, et al.
Publicado: (2023) -
Optimizing the Procedure to Manufacture Clinical-Grade NK Cells for Adoptive Immunotherapy
por: Fernández, Adrián, et al.
Publicado: (2021) -
The JAK inhibitor ruxolitinib abrogates immune hepatitis instigated by concanavalin A in mice
por: Shaker, Mohamed E., et al.
Publicado: (2022) -
Familial CD45RA(–) T cells to treat severe refractory infections in immunocompromised patients
por: Al-Akioui Sanz, Karima, et al.
Publicado: (2023)